leishmania major

Moxipraquine is a novel 8-aminoquinolone compound with anti-infective activity against Trypanosoma cruzi. Moxipraquine effectively inhibited parasitemia but did not eradicate infections in mice or guinea pigs. Moxipraquine was effective against experimental infections of Leishmania major, Lactobacillus mexicanus, and Lactobacillus brasiliensis, but was Ineffective.

SID 26681509 is a selective, reversible and competitive human cathepsin L inhibitor (IC50 of 56 nM).

Insecticidal agent 19 (Compound 7b) exhibits antimalarial activity by inhibiting dihydrofolate reductase-thymidylate synthase (DHFR-TS) and pteridine reductase 1 (PTR1) through the folate metabolic pathway. This compound also inhibits the promastigote and amastigote forms of Leishmania major, with IC50 values of 1.43 μM and 3.78 μM, respectively.

Antileishmanial agent-3 (Compound 13) effectively inhibits the growth of *Leishmania major* [1].

SID 26681509 quarterhydrate is a reversible, potent, selective, competitive inhibitor of human cathepsin L (IC50: 56 nM). SID 26681509 inhibits in vitro propagation of Plasmodium falciparum (IC50: 15.4 μM) and inhibits Leishmania major (IC50: 12.5 μM) and does not inhibit histone G activity.

Antileishmanial agent-13, a quinoline-isatin hybrid, functions as an antileishmanial agent targeting the L. Major Leishmania strain through an anti-folate mechanism. This compound exhibits potent inhibition of both the promastigote and amastigote forms, boasting IC50 values of 0.604 μM and 0.508 μM, respectively.

Antileishmanial agent-16 (compound 14c), an anti-Leishmania agent, exhibits potent activity against Leishmania major promastigotes (IC50 = 0.59 µM) and amastigotes (IC50 = 0.81 µM), while maintaining a favorable safety profile in mammalian cells (VERO cells) [1].

Eugenitin, a polyketide from Mycoleptodiscus indicus, exhibits inhibitory activity against Leishmania major with an LD50 of 39.9 μM and demonstrates low cytotoxicity (IC50 >131 μM) in various human cancer cell lines [1].

Nyasol may have potential to be developed as medicines for the treatment of allergies by inhibiting the activation of mast cells. Nyasol shows anti-inflammatory properties by inhibiting iNOS expression; it also has antifungal activity, it is significantly